Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence.
Sign Up to like & getrecommendations! Published in 2025 at "Pulmonology"
DOI: 10.1080/25310429.2025.2457856
Abstract: BACKGROUND Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This… read more here.
Keywords: real world; non squamous; world; world evidence ... See more keywords
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9521
Abstract: 9521Background: In a previous analysis of KEYNOTE-189 (NCT02578680), we showed that tissue TMB (tTMB) assessed by whole-exome sequencing was not significantly associated with efficacy in either arm... read more here.
Keywords: chemo; evaluation blood; keynote 189; tmb btmb ... See more keywords
The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Translational lung cancer research"
DOI: 10.21037/tlcr-20-874
Abstract: Transl Lung Cancer Res 2020 | http://dx.doi.org/10.21037/tlcr-20-874 Lung adenocarcinoma accounts for approximately 60% of all cases of non-small cell lung cancer (NSCLC). With the progression of genomic medicine, precision oncology has contributed to improve survival… read more here.
Keywords: keynote 189; lung cancer; cancer; oncology ... See more keywords